• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Market Analysis Latest ASX News

Incannex Healthcare Keeps Rising (ASX:IHL)

Like 0

By Carl Wittkopp, Tuesday, 06 October 2020

The Incannex Healthcare Ltd [ASX:IHL] share price has risen 6.17% today, to trade at 8.6 cents at the time of writing. The Melbourne-based cannabinoid pharmaceuticals company announced record sales for the September quarter of 2020.

The Incannex Healthcare Ltd [ASX:IHL] share price has risen 6.17% today, to trade at 8.6 cents at the time of writing.

The Melbourne-based cannabinoid pharmaceuticals company announced record sales for the September quarter of 2020.asx ihl share price movement

Source: Optuma

What’s happening at Incannex Healthcare?

Incannex Healthcare is involved in clinical stage cannabinoid pharmaceutical development. The company is currently focusing on four clinical programs in the hope of gaining FDA approval.

These include treatments for:

  • Obstructive Sleep Apnoea (‘OSA’)
  • Traumatic Brain Injury (‘TBI’)/Concussion
  • Sepsis Associated Acute Respiratory Distress Syndrome (‘SAARDS’)
  • Temporomandibular Joint Disorder (‘TMJD’)

The company announced recently that the cannabinoid arm of the business recorded a strong sales month, with $695,000 in cash receipts.

It may not sound like much, but for context, they used to run a dental products business.

CEO and Managing Director of Incannex Healthcare, Mr Joel Latham, said:

‘The September 2020 quarter is the first quarter in which cannabinoid products were the sole contributor to our revenues. Therefore, I am delighted to report that our most significant quarter of cash sales has come immediately after Incannex finalised its transition into a pure play pharmaceutical development company.’

This was coupled with the recent competition of a capital raise that pulled in $10 million.

With over $12 million in cash, Incannex they can now focus on expanding their new business.

Where to from here for the Incannex share price?

With a market cap of $65.06 million, the company is on the small side. However, with the cannabinoid market expected to expand to US$44 billion by 2024, the company may have room to grow.

IHL ASX share price movement

Source: Optuma

The IHL share price moved up strongly in the last two weeks, should this continue then the levels of 8.8 and 9.6 cents may become the focus.

With the last two weeks pushing up on higher volume, this may indicate buyers are willing to push the price up.

On the downside, should the IHL price turn and retrace, then the levels of 7 and 5.8 cents may come into play.

Regards,

Carl Wittkopp,
For Money Morning

PS: Check out these four excellent small-caps.

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Carl Wittkopp

Carl’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • OpenAI and Microsoft Divorce?: Why this could be good for you
    By Charlie Ormond

    While breakups are rarely pretty, this one might actually benefit investors willing to look beyond the drama.

  • Three Lithium Stocks in the Buy Zone
    By Murray Dawes

    Lithium stocks jumped this week, so Murray and Callum discuss whether this could be the beginning of the second boom in lithium stocks. They also discuss a fund manager that is recovering and looking cheap

  • Every Australian Investor Has a Stake in Mining
    By James Cooper

    With its deep pool of retirement capital, Australia is on track to become the world’s primary destination for resource markets.

Primary Sidebar

Latest Articles

  • OpenAI and Microsoft Divorce?: Why this could be good for you
  • Three Lithium Stocks in the Buy Zone
  • Every Australian Investor Has a Stake in Mining
  • The next wave of AI winners
  • Could the US People Repudiate the National Debt?

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988